Answers are grounded in this paper and cite their sources.
Hypoxia, a hallmark feature of the tumor microenvironment, not only compromises the effectiveness of conventional oxygen‐dependent photosensitizers (PSs) but also contributes to enhanced tumor malignancy and immunosuppression. To address these challenges, we developed an endoplasmic reticulum (ER) targeting PS, ER‐N , which showed O 2 ‐independent photoinduced carbene formation, and could activate robust antitumor immune activation via synergistic induction of ferroptosis and apoptosis. Mechanistically, ER‐N induces severe ER stress via activating the inositol‐requiring enzyme 1 (IRE‐1) and PKR‐like ER‐resident kinase (PERK) pathways, resulting in apoptotic cell death. Concurrently, ER‐N significantly triggers ferroptosis through light‐mediated downregulation of multiple ferroptosis‐suppressing proteins, including glutathione peroxidase 4 (GPX4), thioredoxin (TRX), solute carrier 7A11 (SLC7A11), and ferroptosis suppressor protein 1 (FSP1). This approach is particularly advantageous for overcoming intractable tumor cells that exhibit both apoptosis resistance and one or two mechanisms that suppress ferroptosis. Notably, ER‐N not only maintains high phototoxicity under hypoxia comparable to that under normoxia, but also induces distinct immunogenic cell death (ICD) and promotes immune activation signatures in vivo. This study establishes a robust strategy for designing high‐performance PSs against hypoxic tumors, offering significant potential for advancing precision cancer photoimmunotherapeutics.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: